Clinicopathological characteristics, evolution, treatment pattern and outcomes of hormone-receptor-positive/HER2-low metastatic breast cancer.

Front Endocrinol (Lausanne) · 2023 · PMC10595148 · PMID 37881502

Europe PMC DOI

hedged sentences

0.0670

closest p · 1.3× alpha

0.0670

boldest claim

The sentences

near-significantp=0.067so close (0.05 < p ≤ 0.1)

Without capecitabine, the PFS was 9.30 months for HER2-zero and 7.95 months for HER2-low, a near-significant difference (p=0.067, HR 0.821, 95% CI 0.665-1.014, Figure 5D ).

also in 1,669 other papers

did not reach statistical significanceno p-value reported

Variations were observed in PFS among different patterns of HER2 evolution during 1st-2nd line endocrine therapy; however, these differences did not reach statistical significance (HER2-zero to HER2-zero vs.

also in 75,281 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.